Valneva SE
PAR:VLA

Watchlist Manager
Valneva SE Logo
Valneva SE
PAR:VLA
Watchlist
Price: 3.82 EUR 1.17% Market Closed
Market Cap: 656.9m EUR

Valneva SE
Total Current Liabilities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Valneva SE
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Valneva SE
PAR:VLA
Total Current Liabilities
€125.7m
CAGR 3-Years
-34%
CAGR 5-Years
4%
CAGR 10-Years
12%
Nanobiotix SA
PAR:NANO
Total Current Liabilities
€63m
CAGR 3-Years
14%
CAGR 5-Years
30%
CAGR 10-Years
28%
Inventiva SA
PAR:IVA
Total Current Liabilities
€120.7m
CAGR 3-Years
71%
CAGR 5-Years
37%
CAGR 10-Years
N/A
Cellectis SA
PAR:ALCLS
Total Current Liabilities
$167.4m
CAGR 3-Years
47%
CAGR 5-Years
24%
CAGR 10-Years
7%
DBV Technologies SA
PAR:DBV
Total Current Liabilities
$49.4m
CAGR 3-Years
18%
CAGR 5-Years
-3%
CAGR 10-Years
20%
Eurobio Scientific SA
PAR:ALERS
Total Current Liabilities
€54.6m
CAGR 3-Years
16%
CAGR 5-Years
7%
CAGR 10-Years
17%
No Stocks Found

Valneva SE
Glance View

Market Cap
620.4m EUR
Industry
Biotechnology

Valneva SE is a biotech company. The company is headquartered in Saint-Herblain, Pays De La Loire and currently employs 722 full-time employees. The company went IPO on 2007-06-28. The firm's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The firm has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The firm is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.

VLA Intrinsic Value
11.85 EUR
Undervaluation 68%
Intrinsic Value
Price

See Also

What is Valneva SE's Total Current Liabilities?
Total Current Liabilities
125.7m EUR

Based on the financial report for Jun 30, 2025, Valneva SE's Total Current Liabilities amounts to 125.7m EUR.

What is Valneva SE's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
12%

Over the last year, the Total Current Liabilities growth was 23%. The average annual Total Current Liabilities growth rates for Valneva SE have been -34% over the past three years , 4% over the past five years , and 12% over the past ten years .

Back to Top